Syngene International enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


14,780	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
529	685	978	599	914
9.4	9.4	120	142	575
14,261	—	—	—	—
−520	−675	−858	−457	−339
₹353.95	—	—	—	—

4,868	4,849	4,846	4,399	4,193
0.2%	0.2%	2.5%	3.2%	13.7%
0.00×	—	—	—	—

4.05×	—	—	—	—
18.99×	—	—	—	—
47.27×	—	—	—	—
26.07×	—	—	—	—
3,522	3,739	3,642	3,489	3,193
751	919	1,042	1,014	934
302	466	609	589	568
—	915	1,168	1,042	824
547	547	398	531	305
—	545	394	526	298
—	368	770	511	518

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SYNGENE₹366.85

Syngene International Ltd.

· Pharma & Health

₹ CrorePeersSAILIFE DIVISLAB WOCKPHARMA GLAND ASTERDM PPLPHARMA COHANCE LALPATHLABMcap ₹14,780 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	14,780.4
- Cash, Equiv & ST Investments	913.9	598.9	977.6	684.7	529.2
+ Total Debt	575.3	141.7	119.6	9.4	9.4
Enterprise Value	—	—	—	—	14,260.6
Net Debt (memo)	-338.6	-457.2	-858.0	-675.3	-519.8
EV per Share	—	—	—	—	353.95

Total Capital	4,193.3	4,399.4	4,846.4	4,848.5	4,868.2
Total Debt/Total Capital	13.72	3.22	2.47	0.19	0.19
Total Debt/EV	—	—	—	—	0.00

EV/Sales	—	—	—	—	4.05
EV/EBITDA	—	—	—	—	18.99
EV/EBIT	—	—	—	—	47.27
EV/Free Cash Flow	—	—	—	—	26.07
Reference Items — Trailing FY Values
Sales	3,192.9	3,488.6	3,642.4	3,738.7	3,522.3
EBITDA	934.4	1,014.4	1,041.8	918.5	750.8
EBIT	567.9	588.5	609.2	465.6	301.7
Operating Cash Flow	823.5	1,042.1	1,167.6	915.2	—
Free Cash Flow	305.2	531.3	397.5	547.0	547.0
FCFF (free cash flow to the firm)	297.7	526.2	394.1	544.6	—
Capital Expenditure	518.3	510.8	770.1	368.2	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.